BRVE

20.2805.24%
TM

Travis Murdoch

CEO, President & Director

Dr. Travis Murdoch, M.D., M.Sc. & B.S., has been Chief Executive Officer of Braveheart Bio, Inc. since July 2025, President since October 2025 and its Director since September 2025. From February 2020 to January 2023, he was a Director of Karius, Inc. He is a Co-Founder and Director of Ollin Biosciences Inc. He served as Chief Executive Officer and President at Human Immunology Biosciences, Inc and also served as it's Director. He is Partner of Monograph Capital. He served as an Independent Director at Zymergen, Inc. since September 2020 until October 18, 2022. He was a life sciences investor with Softbank Vision Fund. Dr. Murdoch has served as an Investment Director at Softbank Investment Advisers since January 2018, where he focuses on life sciences investments. Prior to that, Dr. Murdoch served as a Principal at Third Rock Ventures from 2017 to 2018, where he was part of the founding teams of Ambys Medicines and Rheos Medicines. Dr. Murdoch is a director selected to serve on board of directors by SVF Excalibur (Cayman) Limited. Prior to that, Dr. Murdoch served as a Gastroenterologist and Internist at Alberta Health Sciences from 2013 to 2018 and a consultant at McKinsey and Company from 2015 to 2017. He trained in gastroenterology with a focus on inflammatory bowel diseases (IBD) at the University of Calgary and internal medicine at the University of Toronto. Dr. Murdoch holds a M.S. in integrated immunology from University of Oxford as a Rhodes Scholar, as well as a M.D. and Bachelor of Medical Science from the University of Alberta.

Positions